

# Stock Sentiment Analysis Report

Revvity (RVTY)

Analysis Period: 2026-03-14 to 2026-04-13 (30 days)

Generated: 2026-04-13 10:20:54

# Executive Summary


Sentiment analysis for Revvity (RVTY) from 2026-03-14 to 2026-04-13. Analyzed 74 items across FDA and news sources.

## Sentiment Breakdown

Category	Count	Percentage
Positive	24	32.4%
Negative	14	18.9%
Neutral	36	48.6%
<b>Total</b>	<b>74</b>	<b>100.0%</b>

**Overall Sentiment: NEUTRAL**

## Sentiment Trend Over Time



## Key Findings

No key findings available.

## Top Positive Events

Title	Source	Date	Score
Nephron Research gets more bullish on Revvity, upg...	news	2026-03-26	0.991
[Latest] Global Environmental Mass Spectrometry Ma...	news	2026-04-02	0.859
Catabolism of extracellular glutathione supplies c...	news	2026-03-18	0.856
Revvity Inc. stock outperforms competitors on stro...	alpha_vantage	2026-04-08	0.711
Revvity Inc. stock outperforms competitors on stro...	alpha_vantage	2026-04-02	0.711

## Top Negative Events

Title	Source	Date	Score
The E3 ubiquitin ligase mechanism specifying targe...	news	2026-03-18	-0.778
Ectopic NMDAR expression in cancer unmasks germlin...	news	2026-03-25	-0.660
Feasibility of deep learning-based cancer detectio...	pubmed	2026-04-13	-0.660
A $\mu$ -opioid receptor superagonist analgesic with mi...	news	2026-04-01	-0.612
Revvity Inc. stock underperforms Monday when compa...	alpha_vantage	2026-03-30	-0.458